Literature DB >> 17200202

Unique matrix structure in the rough endoplasmic reticulum cisternae of pseudoachondroplasia chondrocytes.

Thomas M Merritt1, Roger Bick, Brian J Poindexter, Joseph L Alcorn, Jacqueline T Hecht.   

Abstract

Mutations in cartilage oligomeric matrix protein (COMP) cause two skeletal dysplasias, pseudoachondroplasia (PSACH) and multiple epiphyseal dysplasia (MED/EDM1). Because COMP exists as a homopentamer, only one mutant COMP subunit may result in an abnormal complex that is accumulated in expanded rough endoplasmic reticulum (rER) cisternae, a hallmark of PSACH. Type IX collagen and matrilin-3 (MATN3), also accumulate in the rER cisternae of PSACH chondrocytes, but it is unknown how mutant COMP interacts with these proteins. The studies herein focus on defining the organization of these intracellularly retained proteins using fluorescence deconvolution microscopy. A unique matrix organization was identified in which type II procollagen formed a central core surrounded by a protein network of mutant COMP, type IX collagen, and MATN3. This pattern of matrix organization was found in multiple cisternae from single chondrocytes and in chondrocytes with different COMP mutations, indicating a common pattern of interaction. This suggests that stalling of mutant COMP and an interaction between mutant COMP and type II procollagen are initiating events in the assembly of matrix in the rER, possibly explaining why the material is not readily cleared from the rER. Altogether, these data suggest that mutant COMP initiates and perhaps catalyzes premature intracellular matrix assembly.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17200202      PMCID: PMC1762700          DOI: 10.2353/ajpath.2007.060530

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  52 in total

1.  A recurrent R718W mutation in COMP results in multiple epiphyseal dysplasia with mild myopathy: clinical and pathogenetic overlap with collagen IX mutations.

Authors:  E Jakkula; J Lohiniva; A Capone; L Bonafe; M Marti; V Schuster; A Giedion; G Eich; E Boltshauser; L Ala-Kokko; A Superti-Furga
Journal:  J Med Genet       Date:  2003-12       Impact factor: 6.318

2.  Calreticulin, PDI, Grp94 and BiP chaperone proteins are associated with retained COMP in pseudoachondroplasia chondrocytes.

Authors:  J T Hecht; E Hayes; M Snuggs; G Decker; D Montufar-Solis; K Doege; F Mwalle; R Poole; J Stevens; P J Duke
Journal:  Matrix Biol       Date:  2001-07       Impact factor: 11.583

3.  Up-regulation of cartilage oligomeric matrix protein at the onset of articular cartilage degeneration in a transgenic mouse model of osteoarthritis.

Authors:  H Salminen; M Perälä; P Lorenzo; T Saxne; D Heinegård; A M Säämänen; E Vuorio
Journal:  Arthritis Rheum       Date:  2000-08

4.  Serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and knee osteoarthritis.

Authors:  M Wisłowska; B Jabłońska
Journal:  Clin Rheumatol       Date:  2004-11-18       Impact factor: 2.980

Review 5.  COMP mutation screening as an aid for the clinical diagnosis and counselling of patients with a suspected diagnosis of pseudoachondroplasia or multiple epiphyseal dysplasia.

Authors:  Jason Kennedy; Gail Jackson; Simon Ramsden; Jacky Taylor; William Newman; Michael J Wright; Dian Donnai; Rob Elles; Michael D Briggs
Journal:  Eur J Hum Genet       Date:  2005-05       Impact factor: 4.246

6.  Interactions between the cartilage oligomeric matrix protein and matrilins. Implications for matrix assembly and the pathogenesis of chondrodysplasias.

Authors:  Henning H Mann; Suat Ozbek; Jürgen Engel; Mats Paulsson; Raimund Wagener
Journal:  J Biol Chem       Date:  2004-04-09       Impact factor: 5.157

7.  Mice lacking alpha 1 (IX) collagen develop noninflammatory degenerative joint disease.

Authors:  R Fässler; P N Schnegelsberg; J Dausman; T Shinya; Y Muragaki; M T McCarthy; B R Olsen; R Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

8.  Cartilage oligomeric matrix protein shows high affinity zinc-dependent interaction with triple helical collagen.

Authors:  K Rosenberg; H Olsson; M Mörgelin; D Heinegård
Journal:  J Biol Chem       Date:  1998-08-07       Impact factor: 5.157

9.  Matrilin-3 is dispensable for mouse skeletal growth and development.

Authors:  Yaping Ko; Birgit Kobbe; Claudia Nicolae; Nicolai Miosge; Mats Paulsson; Raimund Wagener; Attila Aszódi
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

10.  Mutations in exon 17B of cartilage oligomeric matrix protein (COMP) cause pseudoachondroplasia.

Authors:  J T Hecht; L D Nelson; E Crowder; Y Wang; F F Elder; W R Harrison; C A Francomano; C K Prange; G G Lennon; M Deere
Journal:  Nat Genet       Date:  1995-07       Impact factor: 38.330

View more
  35 in total

1.  The evolution of thrombospondins and their ligand-binding activities.

Authors:  Amber A Bentley; Josephine C Adams
Journal:  Mol Biol Evol       Date:  2010-04-28       Impact factor: 16.240

Review 2.  Thrombospondins and novel TSR-containing proteins, R-spondins, regulate bone formation and remodeling.

Authors:  Kurt D Hankenson; Mariya T Sweetwyne; Hailu Shitaye; Karen L Posey
Journal:  Curr Osteoporos Rep       Date:  2010-06       Impact factor: 5.096

Review 3.  Genetic diseases of connective tissues: cellular and extracellular effects of ECM mutations.

Authors:  John F Bateman; Raymond P Boot-Handford; Shireen R Lamandé
Journal:  Nat Rev Genet       Date:  2009-03       Impact factor: 53.242

4.  Mutant cartilage oligomeric matrix protein (COMP) compromises bone integrity, joint function and the balance between adipogenesis and osteogenesis.

Authors:  Francoise Coustry; Karen L Posey; Tristan Maerz; Kevin Baker; Annie M Abraham; Catherine G Ambrose; Sabah Nobakhti; Sandra J Shefelbine; Xiaohong Bi; Michael Newton; Karissa Gawronski; Lindsay Remer; Alka C Veerisetty; Mohammad G Hossain; Frankie Chiu; Jacqueline T Hecht
Journal:  Matrix Biol       Date:  2018-01-05       Impact factor: 11.583

Review 5.  Novel therapeutic interventions for pseudoachondroplasia.

Authors:  Karen L Posey; Jacqueline T Hecht
Journal:  Bone       Date:  2017-03-21       Impact factor: 4.398

6.  Ribozyme-mediated reduction of wild-type and mutant cartilage oligomeric matrix protein (COMP) mRNA and protein.

Authors:  Joseph L Alcorn; Thomas M Merritt; Mary C Farach-Carson; Huiqui H Wang; Jacqueline T Hecht
Journal:  RNA       Date:  2009-02-23       Impact factor: 4.942

7.  RNAi reduces expression and intracellular retention of mutant cartilage oligomeric matrix protein.

Authors:  Karen L Posey; Peiman Liu; Huiqiu R Wang; Alka C Veerisetty; Joseph L Alcorn; Jacqueline T Hecht
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

8.  The crystal structure of the signature domain of cartilage oligomeric matrix protein: implications for collagen, glycosaminoglycan and integrin binding.

Authors:  Kemin Tan; Mark Duquette; Andrzej Joachimiak; Jack Lawler
Journal:  FASEB J       Date:  2009-03-10       Impact factor: 5.191

9.  An inducible cartilage oligomeric matrix protein mouse model recapitulates human pseudoachondroplasia phenotype.

Authors:  Karen L Posey; Alka C Veerisetty; Pieman Liu; Huiqiu R Wang; Brian J Poindexter; Roger Bick; Joseph L Alcorn; Jacqueline T Hecht
Journal:  Am J Pathol       Date:  2009-09-17       Impact factor: 4.307

10.  The interaction of Thrombospondins with extracellular matrix proteins.

Authors:  Kemin Tan; Jack Lawler
Journal:  J Cell Commun Signal       Date:  2009-10-16       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.